Business
PRTC to Present at Jefferies US Conference
PRTC to Present at Jefferies US Conference.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 5375A PureTech Health PLC 30 May 2019 \n\n30 May 2019\n \nPureTech Health plc\n \nPureTech Health to Present at Jefferies 2019 Healthcare Conference\n \nPureTech Health plc (LSE: PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that Daphne Zohar, founder and chief executive officer, will present at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, 5 June, at 11:30 AM EDT. A webcast of the presentation will be available at http://puretechhealth.com/investors under the Reports and Presentations tab.\n \nAbout PureTech Health\nPureTech Health (LSE: PRTC) is an advanced biopharmaceutical company developing BIG medicines for dysfunctions of the Brain-Immune-Gut axis. The Company has gained deep insights into the connection between these systems and the resulting role in diseases that have proven resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech Health is developing new categories of medicines with the potential to have great impact on people with serious diseases.\n \nPureTech Health is advancing a rich pipeline of innovative therapies with an unbiased, non-binary, and capital efficient R&D model across its affiliates and its internal labs. PureTech's affiliates include seven clinical-stage platforms, including one product that has been cleared by the US Food and Drug Administration (FDA) and a second product candidate that has been filed with the FDA for review, and several other novel preclinical programmes. The PureTech Health pipeline includes ground-breaking platforms and therapeutic candidates that were developed in collaboration with some of the world's leading experts.\n \nPureTech's internal research and development is centred on tissue-selective immunomodulation for the treatment of oncology, autoimmune, and CNS-related disorders, with a near-term focus on targeting newly-discovered, foundational immunosuppressive mechanisms in oncology and novel approaches that harness the lymphatic infrastructure.\n \nFor more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.\n \nForward Looking Statement\nThis press release contai...